Cargando…

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment

BACKGROUND AND AIMS: Fibrosis-4 (FIB-4) index is a HCC predictor in chronic hepatitis B (CHB) patients. However, little is known about whether FIB-4 helps identify non-cirrhotic CHB patients with minimal HCC risk after prolonged nucleos(t)ide analogue (NA) therapy. METHODS: A total of 1936 ethnicall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Tai-Chung, Choi, Jonggi, Nguyen, Mindie H., Peng, Cheng-Yuan, Siakavellas, Spyros, Papatheodoridis, George, Wang, Chia-Chi, Lim, Young-Suk, Lai, Hsueh-Chou, Trinh, Huy N., Wong, Christopher, Wong, Clifford, Zhang, Jian, Li, Jiayi, Kao, Jia-Horng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863859/ https://www.ncbi.nlm.nih.gov/pubmed/33547557 http://dx.doi.org/10.1007/s12072-020-10124-z

Ejemplares similares

Evaluation of fibrosis in cirrhotic elderly patients with HCC
por: Pesce, A, et al.
Publicado: (2011)

Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
por: Hoang, Joseph K., et al.
Publicado: (2016)

In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC
por: Ding, Bisha, et al.
Publicado: (2019)

Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver
por: Schütte, Kerstin, et al.
Publicado: (2014)

Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls
por: Vlachogiannakos, Jiannis, et al.
Publicado: (2021)

Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
por: Ito, Takanori, et al.
Publicado: (2023)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview
por: Tampaki, Maria, et al.
Publicado: (2023)

Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2020)

Antiviral therapy of HCV in the cirrhotic and transplant candidate
por: Herrine, Steven K., et al.
Publicado: (2006)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Regional Ischemic Preconditioning Has Clinical Value in Cirrhotic HCC Through MAPK Pathways
por: Wang, Liming, et al.
Publicado: (2018)

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy
por: Huang, Daniel Q., et al.
Publicado: (2020)

Deal a death blow! HCC in cirrhotics – thrombotic complications: their frequency, characteristics, and risk factors
por: Mahmood, Khalid, et al.
Publicado: (2018)

Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B
por: Huang, Daniel Q., et al.
Publicado: (2023)

Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B
por: Wang, Christina, et al.
Publicado: (2016)

Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
por: Kostas, Athanasios, et al.
Publicado: (2017)

A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
por: Chen, Chien-Hung, et al.
Publicado: (2022)

Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
por: SALVI, ALESSANDRO, et al.
Publicado: (2012)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
por: Sun, Na, et al.
Publicado: (2020)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy?
por: Jin, Chen, et al.
Publicado: (2017)

Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study
por: Coppola, Nicola, et al.
Publicado: (2016)

TIPS Is Not Associated with a Higher Risk of Developing HCC in Cirrhotic Patients: A Systematic Review and Meta-analysis
por: Chen, Bin, et al.
Publicado: (2019)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic Patients
por: Zhou, Hang, et al.
Publicado: (2021)

HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?
por: Costentin, Charlotte E., et al.
Publicado: (2021)

Reduced Cortical Complexity in Cirrhotic Patients with Minimal Hepatic Encephalopathy
por: Chen, Qiu-Feng, et al.
Publicado: (2020)

Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients
por: Pagnini, Cristiano, et al.
Publicado: (2018)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Prognosis of critically ill cirrhotic versus non-cirrhotic patients: a comprehensive score-matched study
por: Fu, Chung-Ming, et al.
Publicado: (2014)

The Combination of AFP and “Up-To-Seven” Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients
por: Zhang, Da-li, et al.
Publicado: (2022)

HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
por: Emamaullee, Juliet A., et al.
Publicado: (2019)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy
por: Villani, Rosanna, et al.
Publicado: (2018)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
por: Varbobitis, Ioannis, et al.
Publicado: (2016)

Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000–2015
por: Liu, Anne, et al.
Publicado: (2018)

Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California
por: Toy, Mehlika, et al.
Publicado: (2018)

Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy
por: Thomsen, Karen Louise, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2odn6d26cdrh6qujpcppqko23j